Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...4344454647484950515253...143144»
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer. (Pubmed Central) -  Jan 27, 2022   
    Our results represent a potentially significant discovery that explains the mechanisms of NDRG1 in CTX resistance. NDRG1 could be a promising biomarker to predict optimum responses to CTX, and a key target to enhance CTX activity in the treatment of metastatic CRC (mCRC).
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
    Clinical, Journal:  A Resected Case of Advanced Lower Rectal Cancer with Neoadjuvant Chemotherapy by FOLFOXIRI plus Cetuximab (Pubmed Central) -  Jan 26, 2022   
    The postoperative course was good and the patient was discharged on postoperative day 15. The patient received 8 courses of adjuvant chemotherapy with mFOLFOX6 from the 7th postoperative week and is alive and recurrence-free 6 months after surgery.
  • ||||||||||  Journal:  A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES. (Pubmed Central) -  Jan 26, 2022   
    Finally, we shall discuss two mAbs that are IL-6 antagonists, Tocilizumab and Siltuximab, which are in ongoing clinical trials as potential treatments of COVID-19. The mAbs have profound benefits against chronic and malignant conditions, and the overall purpose of this review is to illustrate the basic pharmacological profiles of mAbs that physicians may find useful in establishing their management protocols.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability. (Pubmed Central) -  Jan 26, 2022   
    In addition to increasing humanness and removing the VH glycosylation site, dynamic light scattering revealed increases in stability, and bio-layer interferometry confirmed minimal changes in binding affinity, with patterns emerging across the humanization method. This work demonstrates the potential to improve the biophysical and clinical properties of first-generation protein therapeutics and highlights the advantages of computationally guided engineering.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, temuterkib (LY3214996) / Eli Lilly, Verzenio (abemaciclib) / Eli Lilly
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jan 25, 2022   
    P1b/2,  N=46, Recruiting, 
    Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer. (Pubmed Central) -  Jan 21, 2022   
    We focus on the mechanisms of resistance to current standard cares, such as chemotherapy (i.e., cisplatin), radiation, and cetuximab. Then, we discuss the strategies to overcome these resistances, including novel combinations and immunotherapy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial termination, Trial primary completion date:  Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 (clinicaltrials.gov) -  Jan 21, 2022   
    P=N/A,  N=161, Terminated, 
    Trial completion date: Aug 2024 --> May 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2024 --> May 2021; As per the HRBs new funding model, HRBs investment will not support costs associated with routine patient care or translational studies, biobanks, patient registries and questionnaires. Therefore, a decision was made to cease further study follow up.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Journal:  Panitumumab and cetuximab affect differently miRNA expression in colorectal cancer cells. (Pubmed Central) -  Jan 20, 2022   
    After the bioinformatics two-phase process, 5 miR rarely described before could be potential actors of anti-EGFR monoclonal antibody resistance: miR-95-3p, miR-139-5p, miR-145-5p, miR-429 and miR-1247-5p. In vivo, we detected the expression of miR-139-5p and miR-145-5p in serum of patients with metastatic CRC.
  • ||||||||||  monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
    Trial completion, IO biomarker, Metastases:  A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) -  Jan 19, 2022   
    P1/2,  N=383, Completed, 
    These results suggested a novel molecular mechanism by which LMTK3 participates in the development of CTX resistance in CRC. Active, not recruiting --> Completed
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
    Journal:  K determination from time-resolved experiments on live cells with LigandTracer and reconciliation with end-point flow cytometry measurements. (Pubmed Central) -  Jan 18, 2022   
    In this study, we also compared time-resolved LigandTracer data with end-point K determination from flow cytometry experiments and hypothesize that discrepancies between these two approaches, when they exist, generally come from flow cytometry titration curves being acquired prior to full equilibration of the system. Our data, however, show that knowledge of the kinetics of the interaction allows to reconcile the data obtained by flow cytometry and LigandTracer and demonstrate the complementarity of these two methods.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Early detection of treatment futility in patients with metastatic colorectal cancer. (Pubmed Central) -  Jan 15, 2022   
    We have identified changes in the metabolome that appear within 1 week of starting treatment associated with treatment futility. The novel approach described is applicable to future efforts in developing a biomarker for early assessment of treatment efficacy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Most Cited Articles in Head and Neck Oncology. (Pubmed Central) -  Jan 14, 2022   
    The top article on the list (Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck-NEJM) has 2243 citations...Our analysis provides an insight into the citation frequency of top cited articles published in HNO to help recognize the quality of the works, discoveries and the trends steering the study of HNO. This is also a modern reading list for young HNO scientist.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Retrospective data, Journal:  Network Meta-analysis of First-Line Systemic Treatment for Patients With Metastatic Colorectal Cancer. (Pubmed Central) -  Jan 14, 2022   
    Our study supports further investigation into EREG as a predictive biomarker in mCRC. Our study supported the use of FOLFOXIRI plus bevacizumab as the best first-line regimen and potentially effective and safe strategy for the management of patients with mCRC.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases. (Pubmed Central) -  Jan 14, 2022   
    αEGFR-E-P125A treatment reduced endothelial and TNBC motility in vitro more effectively than E-P125A or cetuximab, delivered alone or in combination...αEGFR-E-P125A treatment of TNBC xenografts in vivo inhibited angiogenesis and VM, reduced primary tumor growth and lung metastasis of orthotopically implanted MDA-MB-468 TNBC cells, and markedly decreased lung metastases following intravenous injection of MDA-MB-231-4175 lung-tropic TNBC cells. Combined inhibition of angiogenesis, VM, and TNBC motility mediated by αEGFR-E-P125A is a promising strategy for the prevention of TNBC metastases.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Why combining radiotherapy and IO is challenging (Gold Hall) -  Jan 13, 2022 - Abstract #ECHNOICHNO2022ECHNO_ICHNO_27;    
    P1/2, P3
    The Pembro-Rad study (GORTEC 2015-01) randomised patients with HNC who were unfit to receive platin-based C-RT to RT plus either pembrolizumab or cetuximab...On a brighter note, in an approach not based on ICPI, GORTEC also evaluated the SMAC mimetic (Debio-1143, Xevinapant) in a placebo-controlled trial [NCT02022098] in patients receiving C-RT...Other approaches, including comparison of C-RT with either pembrolizumab or placebo (KEYNOTE-412/NCT03040999) or adjuvant atezolizumab following definitive CRT (ImVOKE-10/NCT03452137) are also being tested...These include: radiation dose-fractionation; volume of irradiated tissues; schedule of immunotherapy relative to RT/C-RT; and optimal choice of immunotherapy agent(s). These matters will be discussed in detail during the presentation.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker guided treatment and monitoring for head and neck cancers (Gold Hall) -  Jan 13, 2022 - Abstract #ECHNOICHNO2022ECHNO_ICHNO_5;    
    Small tumor deposits are hard to detect, not only by imaging, but also by biomarkers. However techniques improve, and exciting new developments are underway.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. (Pubmed Central) -  Jan 13, 2022   
    Triplet chemotherapy with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) is an effective first-line treatment option for patients with metastatic colorectal cancer (mCRC)...Of these 282 patients, 199 (71%) were treated with intensive first-line therapy other than FOLFOXIRI-B, of whom 184 (65%) were treated with oxaliplatin doublets with or without bevacizumab; 14 (5%) with irinotecan doublets with or without bevacizumab, panitumumab, or cetuximab; and 1 (0.4%) with irinotecan with bevacizumab...Considering that most medical oncologists discuss this treatment option, the prescription rate found in this study was below expectations. Awareness of guidelines and trial data seems to contribute to the discussion of available treatment options by medical oncologists, and the findings of this study suggest a need for repeated and continuing medical education.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal, PD(L)-1 Biomarker, IO biomarker:  PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. (Pubmed Central) -  Jan 13, 2022   
    Increased expression and glycosylation of PD-L2 in tumors are an important mechanism for cetuximab therapy refractoriness. Thus, the combination of PD-L2 glycosylation inhibition and cetuximab is a potential therapeutic strategy for cancer.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Imbruvica (ibrutinib) / AbbVie, J&J
    Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker, Metastases:  Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC (clinicaltrials.gov) -  Jan 13, 2022   
    P2,  N=5, Active, not recruiting, 
    Thus, the combination of PD-L2 glycosylation inhibition and cetuximab is a potential therapeutic strategy for cancer. Recruiting --> Active, not recruiting | N=39 --> 5 | Trial primary completion date: Jun 2022 --> Jan 2022
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, PD(L)-1 Biomarker, IO biomarker:  PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer. (Pubmed Central) -  Jan 12, 2022   
    P2
    PD-L1 mutations mediate subclonal immune escape to avelumab in some patients with mCRC expressing high-affinity FcγR3a, which may be a subset experiencing most selective pressure. Future trials evaluating the addition of avelumab to standard treatment in MSS mCRC are warranted especially in this patient subpopulation.